WMT

124.32

+0.74%↑

COST

996.39

+0.02%↑

TGT

121.01

+2.06%↑

72.34

-1.63%↓

DG.US

118.62

+0.7%↑

WMT

124.32

+0.74%↑

COST

996.39

+0.02%↑

TGT

121.01

+2.06%↑

72.34

-1.63%↓

DG.US

118.62

+0.7%↑

WMT

124.32

+0.74%↑

COST

996.39

+0.02%↑

TGT

121.01

+2.06%↑

72.34

-1.63%↓

DG.US

118.62

+0.7%↑

WMT

124.32

+0.74%↑

COST

996.39

+0.02%↑

TGT

121.01

+2.06%↑

72.34

-1.63%↓

DG.US

118.62

+0.7%↑

WMT

124.32

+0.74%↑

COST

996.39

+0.02%↑

TGT

121.01

+2.06%↑

72.34

-1.63%↓

DG.US

118.62

+0.7%↑

Home・Akcijų sąrašas・USANA Health Sciences Inc

USANA Health Sciences Inc

Uždarymo kaina

17.36 -1.48

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

17.06

Max

17.63

Pagrindiniai rodikliai
By Trading Economics
Pajamos	5.1M -1.6M
Pardavimai	13M 226M
P/E Sektoriaus vid.	30.483 28.921
Pelno marža	-0.705
Darbuotojai	1,570
EBITDA	16M 28M

Dividendai
By Dow Jones
Kitas uždarbis	2026-04-21

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-56M 326M
Ankstesnė atidarymo kaina	18.84
Ankstesnė uždarymo kaina	17.36

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

28.405 / 29.84 Palaikymas ir pasipriešinimas

USANA Health Sciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-31 23:31; UTC

Karštos akcijos

Stocks to Watch: Nike, RH, NCino

2026-03-31 22:35; UTC

Uždarbis

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

2026-04-01 00:00; UTC

Įsigijimai, susijungimai, perėmimai

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

2026-03-31 23:50; UTC

Įsigijimai, susijungimai, perėmimai

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

2026-03-31 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

2026-03-31 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

2026-03-31 23:21; UTC

Uždarbis

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

2026-03-31 23:14; UTC

Rinkos pokalbiai

Uždarbis

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

2026-03-31 23:12; UTC

Rinkos pokalbiai

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Loss Widens >000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

2026-03-31 21:46; UTC

Įsigijimai, susijungimai, perėmimai

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

2026-03-31 21:36; UTC

Rinkos pokalbiai

West African Resources's Costs Higher Than Bull Expected -- Market Talk

2026-03-31 21:35; UTC

Uždarbis

Nike Expects China Sales Down 20% in 4Q, CFO Says

2026-03-31 21:35; UTC

Uždarbis

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

2026-03-31 21:35; UTC

Uždarbis

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

2026-03-31 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

2026-03-31 21:33; UTC

Uždarbis

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

2026-03-31 21:32; UTC

Uždarbis

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

2026-03-31 21:28; UTC

Uždarbis

Nike Expects to End 4Q With Elevated Inventory, CFO Says

2026-03-31 21:26; UTC

Uždarbis

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

2026-03-31 21:25; UTC

Uždarbis

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

2026-03-31 21:24; UTC

Rinkos pokalbiai

Uždarbis

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

2026-03-31 21:22; UTC

Uždarbis

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

2026-03-31 21:22; UTC

Uždarbis

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

2026-03-31 21:21; UTC

Uždarbis

Nike's Digital Channel Still Too Promotional, CFO Says

2026-03-31 21:20; UTC

Uždarbis

Nike CEO: Converse Remains Important to Portfolio

Akcijų palyginimas

Kainos pokytis

USANA Health Sciences Inc Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių USANA Health Sciences Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

28.405 / 29.84Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There are no events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę USANA Health Sciences Inc

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.